Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity
Carlos Galán‐Arriola, Rocío Villena-Gutiérrez, M I Higuero-Verdejo, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 4, pp. 1132-1143
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 94
Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection
Gerd Heusch, Ioanna Andreadou, Robert M. Bell, et al.
Redox Biology (2023) Vol. 67, pp. 102894-102894
Open Access | Times Cited: 47
Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota
Hui Lin, Liping Meng, Zhenzhu Sun, et al.
Circulation Heart Failure (2021) Vol. 14, Iss. 10
Open Access | Times Cited: 59
Priorities in Cardio-Oncology Basic and Translational Science
Fadi N. Salloum, Carlo G. Tocchetti, Pietro Ameri, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 6, pp. 715-731
Open Access | Times Cited: 23
PHB2 ameliorates Doxorubicin-induced cardiomyopathy through interaction with NDUFV2 and restoration of mitochondrial complex I function
Mingjie Yang, Miyesaier Abudureyimu, Xiang Wang, et al.
Redox Biology (2023) Vol. 65, pp. 102812-102812
Open Access | Times Cited: 22
Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control
Anabel Díaz-Guerra, Rocío Villena-Gutiérrez, Agustín Clemente‐Moragón, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 217-232
Open Access | Times Cited: 8
Indole‐3‐Lactic Acid Inhibits Doxorubicin‐Induced Ferroptosis Through Activating Aryl Hydrocarbon Receptor/Nrf2 Signalling Pathway
Jiangfang Lian, Hangyuan Guo, Zuoquan Zhong, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 2
Open Access | Times Cited: 1
SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics
Danielle Medina-Hernández, Laura Cádiz, Annalaura Mastrangelo, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 2, pp. 171-184
Open Access | Times Cited: 1
Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart
Sean M. Davidson, Teresa Padró, Sveva Bollini, et al.
Cardiovascular Research (2021) Vol. 117, Iss. 10, pp. 2161-2174
Open Access | Times Cited: 41
Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology
Jaidyn Muhandiramge, John Zalcberg, G. J. van Londen, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 11, pp. 1579-1592
Open Access | Times Cited: 36
Current Status of Experimental Animal Skin Flap Models: Ischemic Preconditioning and Molecular Factors
Ju‐Hee Lee, Hi‐Jin You, Tae-Yul Lee, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5234-5234
Open Access | Times Cited: 32
Remote ischaemic conditioning: defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop
Robert M. Bell, Marina Basalay, Hans Erik Bøtker, et al.
Basic Research in Cardiology (2022) Vol. 117, Iss. 1
Open Access | Times Cited: 32
Recent Advances in Mitochondrial Fission/Fusion-Targeted Therapy in Doxorubicin-Induced Cardiotoxicity
Chayodom Maneechote, Siriporn C. Chattipakorn, Nipon Chattipakorn
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1182-1182
Open Access | Times Cited: 16
Cardio-oncology: chances and challenges
Adriana E. Viñas-Mendieta, A. Gallardo-Grajeda, Teresa López‐Fernández
Basic Research in Cardiology (2024)
Closed Access | Times Cited: 6
Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism
Piotr Szczepaniak, Mateusz Siedliński, Diana Hodorowicz‐Zaniewska, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 13
Open Access | Times Cited: 25
Emodin ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis through the remodeling of gut microbiota composition
Songqing Hu, Jiedong Zhou, Jinjin Hao, et al.
AJP Cell Physiology (2023) Vol. 326, Iss. 1, pp. C161-C176
Closed Access | Times Cited: 13
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity
Andrea Moreno‐Arciniegas, Alberto López García, Malte Kelm, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2213-2222
Open Access | Times Cited: 5
Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment
Brian Sacks, Halil Onal, Rose Martorana, et al.
BMC Pharmacology and Toxicology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Remote Ischemic Conditioning for Anthracycline Cardiotoxicity
Borja Ibáñez, María Gomes da Silva
JACC CardioOncology (2023) Vol. 5, Iss. 3, pp. 356-359
Open Access | Times Cited: 12
Remote Ischemic Conditioning in Pediatric Cancer Patients Receiving Anthracycline Chemotherapy
Yiu‐fai Cheung, Vivian Wing‐yi Li, Edwina Kam-fung So, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 3, pp. 332-342
Open Access | Times Cited: 11
Cardioprotection strategies for anthracycline cardiotoxicity
Andrea Moreno‐Arciniegas, Laura Cádiz, Carlos Galán‐Arriola, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Anthracycline-induced cardiotoxicity: emerging mechanisms and therapies
Guanjing Ling, Fei Ge, Weili Li, et al.
Medicine Plus (2025), pp. 100074-100074
Open Access
Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
European Journal of Heart Failure (2025)
Open Access
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies
Valerio Nardone, Dafne Ruggiero, Maria Giovanna Chini, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1059-1059
Open Access
Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways
Salwa R Abo El-Ela, Randa A. Zaghloul, Laila A. Eissa
Nutrition (2022) Vol. 102, pp. 111732-111732
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top